Quick Answer
Propanc Biopharma, Inc. reported Stockholders Equity of $13.91 million for the year ending 2025.
- Propanc Biopharma, Inc. showed an increase of +468.0% in Stockholders Equity from 2024 to 2025.
- This data is from Propanc Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$3.64 million | Q3 2020: -$3.24 million | Q4 2020: -$3.61 million | Q1 2021: -$3.00 million | Q3 2021: -$2.31 million | Q4 2021: -$2.93 million | Q1 2022: -$2.95 million | Q3 2022: -$2.77 million | Q4 2022: -$2.92 million | Q1 2023: -$2.94 million | Q3 2023: -$2.99 million | Q4 2023: -$3.56 million | Q1 2024: -$3.70 million | Q2 2024: -$3.78 million | Q3 2024: -$4.11 million | Q4 2024: -$4.16 million | Q1 2025: $18.09 million | Q2 2025: $13.91 million | Q3 2025: $14.36 million | Q4 2025: $10.45 million.
- Over the full 18 years of available data (2008 to 2025), Propanc Biopharma, Inc.'s Stockholders Equity has grown by 16,234.5%.
- Historical annual values: Fiscal year 2025: $13.91 million | Fiscal year 2024: -$3.78 million | Fiscal year 2023: -$3.12 million | Fiscal year 2022: -$3.02 million | Fiscal year 2021: -$3.07 million | Fiscal year 2020: -$3.64 million | Fiscal year 2019: -$4.30 million | Fiscal year 2018: -$6.75 million | Fiscal year 2017: -$5.44 million | Fiscal year 2016: -$2.57 million | Fiscal year 2015: -$3.05 million | Fiscal year 2014: -$1.41 million | Fiscal year 2013: -$792.5 thousand | Fiscal year 2012: -$537.9 thousand | Fiscal year 2011: $10.51 million | Fiscal year 2010: -$186.9 thousand | Fiscal year 2009: -$409.4 thousand | Fiscal year 2008: $85.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: